摘要
目的 :探讨曲美他嗪联合低分子肝素 (LMWH)对老年冠心病心绞痛的临床疗效。方法 :6 8例老年冠心病心绞痛患者随机分成联合治疗组和常规治疗组 ,在常规抗心绞痛疗法基础上 ,联合治疗组加用曲美他嗪和LMWH ,其中曲美他嗪 6 0～ 12 0mg/d ,分 3次口服 ,疗程 30d ;LMWH 0 .3～ 0 .6ml (2 85 0～ 5 70 0IU) ,每日 1～ 2次皮下注射 ,连续 7～ 15d。观察两组临床疗效及随访至治疗后 30d的心脏事件。结果 :联合治疗组总有效率为94 .12 % ,常规治疗组总有效率为 70 .5 9% ,两组疗效比较差异有显著性意义 (P <0 .0 5 )。结论 :老年冠心病心绞痛患者常并发其他心脑血管病、糖尿病等疾患 。
Objective:To study the clinical therapeutic effect of trimetazidine combined with low molecular weight hepacarin(LMWH)in senile coronary heart disease(CHD) angina pectoric(AP).Methods:Sixty-eight patients with CHD Angina Pectoric were randomly divided into combined treatment group and routine treatment group. On the basis of routine treatment, the patients of combined group were treated with trimetazidine and LMWH, [(trimetazidine: 60～120 mg/d, tid, po. for 30 days; LMWH: 0.3～ 0.6 ml(2 850～5 700 IU), qd or bid. hypodemic injection, for 7～15 days)]. Clinical therapeutic effects, routine and dynamic ECG, exercise test, blood pressure monitoring, resistance insulin(RI), nitrogenmonoxide(NO), D-dipolymer and heart accident were studied, followed up for 30 days after treatment.Results:There were no significant difference of age, sex, cardio-cerebral vessel complication, diabets in the two group patients. But the total effective rate was 94.12% in combined group and 70.59% in routine group. There were significant differences (P< 0.05) in two groups.Conclusion:Senile CHD patieats can be treated with trimetazidine and LMWH. The therapeutic effects is satisfactory, safe and easy.
出处
《临床心血管病杂志》
CAS
CSCD
北大核心
2003年第6期356-357,共2页
Journal of Clinical Cardiology
关键词
冠状动脉疾病
心绞痛
曲美他嗪
低分子肝素
Coronary disease
Angina pectoris
Trimetazidine
Low molecular weight hepacarin
